OsafehintiD, RakhlinL, ParkP., et al.SAT-474 Amiodarone-Induced Thyrotoxicosis After Weight Loss Following Sleeve Gastrectomy. J Endocr Soc, 2020; 4,(Suppl 1):SAT–474.
2.
BourronO, CianguraC, BouillotJL., et al.Amiodarone-induced hyperthyroidism during massive weight loss following gastric bypass. Obes Surg, 2007; 17(11):1525–1528; doi: 10.1007/s11695-008-9415-0
3.
AdamsPC, HoltDW, StoreyGC., et al.Amiodarone and its desethyl metabolite: Tissue distribution and morphologic changes during long-term therapy. Circulation, 1985; 72(5):1064–1075; doi: 10.1161/01.cir.72.5.1064
4.
BrienJF, JimmoS, BrennanFJ., et al.Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol, 1987; 65(3):360–364; doi: 10.1139/y87-062
5.
JandacekR, LiuM, TsoP. Interactions of body weight loss with lipophilic toxin storage: Commentary. J Nutr, 2024; 154(3):801–803; doi: 10.1016/j.tjnut.2024.01.018
6.
LigeroC, RieraP, El-AmraniA., et al.Impact of body mass index in the cardioverter efficacy of amiodarone in persistent atrial fibrillation. Pharmaceuticals (Basel), 2024; 17(6); doi: 10.3390/ph17060693
7.
CappellaniD, MarconciniG, ManettiL., et al.Real-life data on the effect of medical therapy for amiodarone-induced thyrotoxicosis on CV events and hospitalizations. J Clin Endocrinol Metab, 2023; 108(6):1298–1307; doi: 10.1210/clinem/dgac756
